We are live on
!
Find out more
GCM
Gladius Capital Management Portfolio holdings
AUM
$1.65B
1-Year Est. Return
25.75%
This Fund
S&P 500
This Quarter
Est. Return
+5.35%
1 Year Est. Return
+25.75%
3 Year Est. Return
+78.03%
5 Year Est. Return
+67.88%
10 Year Est. Return
+218.88%
AUM
$2.05B
AUM Growth
+$329M
(+19%)
Cap. Flow
+$1.88B
Cap. Flow
% of AUM
91.78%
Top 10 Holdings %
Top 10 Hldgs %
68.15%
Holding
481
New
114
Increased
102
Reduced
143
Closed
120
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Russell 2000 ETF
IWM
|
+$6.06M |
| 2 |
Coca-Cola
KO
|
+$3.06M |
| 3 |
Alphabet (Google) Class C
GOOG
|
+$2.91M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
+$2.48M |
| 5 |
Verisk Analytics
VRSK
|
+$924K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$55.5M |
| 2 |
iShares MSCI EAFE ETF
EFA
|
+$26.7M |
| 3 |
Invesco QQQ Trust
QQQ
|
+$15M |
| 4 |
Walmart Inc
WMT
|
+$7.68M |
| 5 |
JPMorgan Chase
JPM
|
+$7.09M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 0.64% |
| 2 | Technology | 0.43% |
| 3 | Industrials | 0.31% |
| 4 | Communication Services | 0.28% |
| 5 | Consumer Staples | 0.27% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
TRUE
276
DELISTED
TrueCar
TRUE
| $26.5K | ﹤0.01% |
11,706
-315
| -3% | -$750 |
|
277
Prenetics Global
PRE
$315M
| $26.3K | ﹤0.01% |
+1,973
| New | +$25.8K |
|
278
Flowers Foods
FLO
$1.53B
| $26.1K | ﹤0.01% |
1,051
-299
| -22% | -$7.92K |
|
279
Motorcar Parts of America
MPAA
$257M
| $25.8K | ﹤0.01% |
3,338
+786
| +31% | +$4.49K |
|
280
NRC Health Common Stock
NRC
$432M
| $25.8K | ﹤0.01% |
593
-204
| -26% | -$8.97K |
|
|
EGRX
281
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
| $25.5K | ﹤0.01% |
1,314
+262
| +25% | +$6.22K |
|
282
Plains GP Holdings
PAGP
$5.15B
| $25.5K | ﹤0.01% |
+1,722
| New | +$23.8K |
|
283
American Public Education
APEI
$975M
| $25.5K | ﹤0.01% |
5,386
+2,311
| +75% | +$12.6K |
|
284
Elanco Animal Health
ELAN
$12.8B
| $25.3K | ﹤0.01% |
2,514
-102
| -4% | -$947 |
|
285
MarketAxess Holdings
MKTX
$5.71B
| $25.1K | ﹤0.01% |
96
-403
| -81% | -$120K |
|
|
MDRX
286
DELISTED
Veradigm Inc. Common Stock
MDRX
| $25K | ﹤0.01% |
1,982
-144
| -7% | -$1.75K |
|
287
Zymeworks
ZYME
$1.6B
| $24.9K | ﹤0.01% |
+2,887
| New | +$25.8K |
|
288
John B. Sanfilippo & Son
JBSS
$993M
| $23.9K | ﹤0.01% |
+204
| New | +$22.9K |
|
|
EEX
289
DELISTED
Emerald Holding
EEX
| $23.8K | ﹤0.01% |
+5,803
| New | +$21.9K |
|
290
Build-A-Bear
BBW
$424M
| $23.7K | ﹤0.01% |
1,108
-412
| -27% | -$9.01K |
|
291
World Kinect Corp
WKC
$2B
| $23.7K | ﹤0.01% |
+1,145
| New | +$27.3K |
|
292
Nuvation Bio
NUVB
$2.14B
| $23.2K | ﹤0.01% |
12,884
-1,418
| -10% | -$2.41K |
|
293
Collegium Pharmaceutical
COLL
$1.15B
| $22.9K | ﹤0.01% |
1,067
-168
| -14% | -$3.81K |
|
294
Orthofix Medical
OFIX
$496M
| $22.8K | ﹤0.01% |
1,263
-470
| -27% | -$8.78K |
|
295
Universal Corp
UVV
$1.3B
| $22.6K | ﹤0.01% |
452
-222
| -33% | -$11.7K |
|
296
Lyell Immunopharma
LYEL
$315M
| $22.1K | ﹤0.01% |
348
-202
| -37% | -$11.2K |
|
297
AnaptysBio
ANAB
$1.59B
| $22K | ﹤0.01% |
+1,082
| New | +$21.9K |
|
|
EQRX
298
DELISTED
EQRx, Inc. Common Stock
EQRX
| $21.6K | ﹤0.01% |
11,607
-2,866
| -20% | -$5.13K |
|
299
Supernus Pharmaceuticals
SUPN
$2.67B
| $21.5K | ﹤0.01% |
+715
| New | +$25K |
|
300
SIGA Technologies
SIGA
$230M
| $21.1K | ﹤0.01% |
4,181
-749
| -15% | -$4.26K |
|
Similar funds
ACM
CCM
BFPW
PP
RIA
GACM
GA
Gladius Capital Management's Q2 2023 Portfolio in Review
As of Q2 2023, Gladius Capital Management held 481 positions worth $2.05B, up 19% from $1.72B the previous quarter. Its ten largest holdings account for 68% of the portfolio.
Gladius Capital Management deployed $1.88B of net new capital in Q2 2023, opening 114 new positions and adding to 102 existing holdings. Its largest new stake was Alphabet (Google) Class C: 25,152 shares worth $3.04M.
By sector, the portfolio is most concentrated in Healthcare at 0.64% of assets, down from 1.1% a quarter earlier, followed by Technology and Industrials.
On the sell side, the largest reduction was State Street SPDR S&P 500 ETF Trust, an estimated $55.5M trimmed.
- Gladius Capital Management's largest Q2 2023 buy was Alphabet (Google) Class C: 25,152 shares worth $3.04M.
- Gladius Capital Management added most to iShares Russell 2000 ETF in Q2 2023, an estimated $6.06M increase.
- Gladius Capital Management's biggest Q2 2023 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $55.5M.
- Gladius Capital Management fully exited iShares MSCI EAFE ETF in Q2 2023, selling an estimated $26.7M.
- Gladius Capital Management's ten largest holdings make up 68% of its $2.05B portfolio in Q2 2023.
- Gladius Capital Management opened 114 new positions and closed 120 in Q2 2023.
- Gladius Capital Management's portfolio value rose 19% quarter-over-quarter to $2.05B.
Based on Gladius Capital Management's 13F filing for Q2 2023, filed 8 Aug 2023.